IMS HEALTH INC Form 8-K January 16, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 16, 2003

 ${\tt IMS\ HEALTH\ INCORPORATED} \\ ({\tt Exact\ name\ of\ registrant\ as\ specified\ in\ its\ charter})$

Delaware 001-14049 06-1506026 (State of (Commission File Number) (IRS Employer incorporation) Identification No.)

1499 Post Road
Fairfield, Connecticut 06824
(Address of principal executive offices) (Zip Code)

(203) 319-4700
(Registrant's telephone number,
 including area code)

N/A

(Former name or former address, if changed since last report)

Items 1-4. Not Applicable.

Item 5. OTHER EVENTS.

On January 9, 2003, IMS Health Incorporated (the "Company") commenced its offer to exchange 0.309 shares of class B common stock of Cognizant Technology Solutions Corporation for each share of the Company's common stock. The Company commenced the exchange offer by mailing an offering circular-prospectus with details of the transaction to its shareholders on January 9, 2003. This report updates and replaces the following pro forma financial information presented in the offering circular-prospectus.

COMPARATIVE PER SHARE DATA

IMS HEALTH PRO FORMA FOR EXCHANGE

	OFFER(1)
EARNINGS PER SHARE FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2001	
Basic	\$0.65
Diluted	0.64
EARNINGS PER SHARE FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2002	
Basic	0.72
Diluted CASH DIVIDENDS PER SHARE DECLARED	0.72
For the twelve months ended December 31,	
2001 For the nine months ended September 30,	0.08
2002 BOOK VALUE PER SHARE	0.06
As of September 30, 2002	\$0.33

⁽¹⁾ The "IMS Health Pro Forma for Exchange Offer" amounts assume that 36,540,129 IMS Health shares are exchanged for 11,290,900 Cognizant shares. However, if we assumed that only 27,400,000 IMS Health shares — the minimum amount that IMS will accept in the exchange offer — are exchanged for 8,466,600 Cognizant shares, then the "IMS Health Pro Forma for Exchange Offer" amounts would not differ from the amounts presented as IMS Health would have accounted for its investment in Cognizant on the cost method of accounting.

1

IMS HEALTH UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

IMS HEALTH

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME YEAR ENDED DECEMBER 31, 1999

	IMS ACTUAL	PRO FORMA ADJUSTMENTS(1)	IMS P
	(DOLLARS AND SH	HARES IN THOUSANDS, EXCEPT	PER SH
Operating revenue Operating and other costs	\$1,397,989 1,058,966	\$(74,084) (57,439)	\$1, 1,
Operating income	339,023	(16,645)	
Interest income (expense), net	635 25,264 (16,480)	(1,263) (5) 4,376(2B)	
Non-operating income, net	9,419	3,108	

Income before provision for income taxes Provision for income taxes	348,442 (98,076)	(13,537) 5,763(2B)	
Income from continuing operations	\$ 250,366 ======	\$ (7,774) =====	\$ ===
Basic earnings per share of common stock from			
continuing operations	\$ 0.80		\$
	========		
Diluted earnings per share of common stock			
from continuing operations	\$ 0.78		\$
	========		
Weighted average number of shares			
outstanding basic	311 , 976	(36,540)(5)	
	========	=======	===
Weighted average number of shares			
outstanding diluted	319,561	(36,540)(5)	
		======	

See Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.

2

IMS HEALTH

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME YEAR ENDED DECEMBER 31, 2000

		PRO FORMA JUSTMENTS(1)	IMS PRO
		IN THOUSANDS, EXCEPT	
Operating revenue Operating and other costs	\$1,424,359 1,287,166	\$ (122,763) (96,634)	\$1,301 1,190
Operating income	137,193	(26,129)	111
Interest (expense) income, net Loss on Gartner investment Gains from investments, net Gain on sale of Erisco Gain on issuance of investees' stock Other expense, net	(13,308) (6,896) 78,139 84,530 9,029	(2,650) (7) 6,979 (2B)	(15 (6 78 84 9 (20
Non-operating income, net	124,120	4,322	128
Income before provision for income taxes Provision for income taxes TriZetto equity loss, net of income tax benefit	261,313 (140,412) (4,777)	(21,807) 9,494 (2B)	239 (130
Income from continuing operations	\$ 116,124	\$ (12,313)	\$ 103
Basic earnings per share of common stock			

from continuing operations	\$ 0.39		\$ =====
Diluted earnings per share of common stock from continuing operations	\$ 0.39		\$ =====
Weighted average number of shares outstanding basic	296 , 077	(36 , 540)(5)	259 =====
Weighted average number of shares outstanding diluted	300,038	(36,540)(5) =====	263 =====

See Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.

3

IMS HEALTH

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME YEAR ENDED DECEMBER 31, 2001

	IMS ACTUAL	PRO FORMA ADJUSTMENTS(1)	
		SHARES IN THOUSANDS,	
Operating revenue Operating and other costs	\$1,332,923 1,008,762	\$(158,969) (123,348)	\$1 , 173 885
Operating income	324,161	(35,621)	288
Interest (expense) income, net Loss on Gartner investment Loss from investments, net Gain (loss) on issuance of investees'	(9,006) (84,880) (27,642)	(2,501) 1,955	(11 (84 (25
stock Other expense, net	(1,490) (17,342)	(5,189) (. 9,234 (.	2B) (8
Non-operating income (loss), net	(140,360)	3,499	 (136
Income before provision for income taxes Provision for income taxes TriZetto equity loss, net of income tax benefit	183,801 (38,415) (6,985)	(32,122) 14,433 (151
Income from continuing operations	\$ 138,401		 \$ 120
Basic earnings per share of common stock from continuing operations	\$ 0.47		===== \$ =====
Diluted earnings per share of common stock from continuing operations	\$ 0.46		\$ =====
Weighted average number of shares outstanding basic	295 , 162	(36,540)(5) 258 =====
Weighted average number of shares			

		=======	=======	=====
outstanding	diluted	300,147	(36,540)(5)	263

See Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.

4

IMS HEALTH

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME NINE MONTHS ENDED SEPTEMBER 30, 2002

	IMS ACTUAL	PRO FORMA ADJUSTMENTS(1)	IMS PRO
		SHARES IN THOUSANDS, EXCEPT	PER SHAR
Operating revenue Operating and other costs	\$1,046,172 727,290	\$ (146,510) (114,553)	\$899, 612,
Operating income	318,882	(31,957)	286 ,
<pre>Interest (expense) income, net Gains from investments, net</pre>	(4,643) 2,450	(1,305)	(5, 2,
stock Other expense, net	7,508 (29,003)	(8,083)(2A) 11,180(2B)	((17,
Non-operating income (loss), net	(23,688)	1,792 	(21,
Income before provision for income taxes Provision for income taxes TriZetto equity loss, net of income tax benefit	295,194 (91,044)	(30,165) 8,308(2A-B)	265, (82,
Income from continuing operations	\$ 203,449	\$ (21,857)	 \$181,
Basic earnings per share of common stock from continuing operations	\$ 0.71	======	===== \$ 0 =====
Diluted earnings per share of common stock from continuing operations	\$ 0.70 ======		\$ 0 =====
Weighted average number of shares outstanding basic	287 , 486	(36,540)(5) ======	250, =====
Weighted average number of shares outstanding diluted	288 , 589	(36,540)(5) ======	252 , =====

See Notes to Unaudited Pro Forma Condensed Financial Information.

IMS HEALTH

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION SEPTEMBER 30, 2002

	IMS ACTUAL	PRO FORMA ADJUSTMENTS(3)
		SHARES IN THOUSANDS,
Assets:		
Current Assets:		
Cash and cash equivalents Accounts receivable, net of allowance for doubtful	\$ 387,972	\$ (123,083)
accounts	247,506	(40,780)
Other receivable	35 , 428	
Other current assets	125,755	10,231
Total Current Assets	796,661	(153,632)
Securities and other investments	21,210	(112)
TriZetto equity investment Property, plant and equipment, net of accumulated	118,167	
depreciation	152,084	(25,905)
Computer software	149,292	
Goodwill	166,638	(878)
Other assets	145,666	(3,587)
Total Assets	\$ 1,549,718	\$ (184,114) =======
Liabilities, Minority Interests and Shareholders' Equity: Current Liabilities:		
Accounts payable	\$ 29,443	\$ (3,202)
Accrued and other current liabilities	187,680	(11,639)(4B)
Short-term debt	381,522	
Accrued income taxes	131,468	(818)
Short-term deferred tax liability	12,220	(12,220)
Deferred revenues	75 , 022	(1,602)
Total Current Liabilities	817,355	(29,481)
Post-retirement and post-employment benefits	41,597	
Long-term debt	175,000	
Other liabilities	183,068	(4,650)
Total Liabilities	1,217,020	(34,131)
Commitments and contingencies		
Minority Interests Shareholders' Equity:	166,193	(64,673) (4A)
Common stock, par value \$.01, authorized 800,000 shares;		
issued 335,045 shares at September 30, 2002	3 , 350	
Capital in excess of par	498,637	
Retained earnings	1,108,050	522,462(4B)
Treasury stock, at cost, 53,648 shares at September 30, 2002		
(90,188 shares on a pro forma basis)(5)	(1,314,445)	(608,028) (4B)
Cumulative translation adjustment	(122, 426)	256
Minimum pension liability adjustment	(3,746)	

Unrealized loss on changes in fair value of cash flow	(3,017)	
hedges	(-,-,	
Unrealized gains on investments, net of tax expense	102	
Total Shareholders' Equity	166,505	(85,310)
Total Liabilities, Minority Interests and Shareholders'		
Equity	\$ 1,549,718	\$(184,114)
	========	=======

See Notes to Unaudited Pro-Forma Condensed Financial Information.

6

NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION (in thousands, except for per share amounts and percentages)

- 1. The adjustments to the unaudited pro forma condensed consolidated statements of income reflect the elimination of the unaudited results of operations of Cognizant (See Cognizant Financial Statements beginning on page F-1 of the offering circular-prospectus), after eliminating intercompany revenues and costs of \$14,820, \$14,273, \$18,809 and \$15,565, for the years ended 1999, 2000 and 2001 and the nine months ended September 30, 2002, respectively.
- 2. In addition, the pro forma adjustments to the unaudited pro forma condensed consolidated statements of income reflect:
 - A. The elimination of the pre-tax gains recognized by IMS Health on the issuance of Cognizant stock in the amounts of \$0, \$0, \$5,189 and \$8,083 for the years ended December 31, 1999, 2000 and 2001 and the nine months ended September 30, 2002, respectively, and the related income tax expense of \$0, \$0, \$1,816 and \$2,834, respectively.
 - B. The elimination of minority interest in the amounts of \$4,376, \$6,979, \$9,234, and \$11,180 for the years ended December 31, 1999, 2000 and 2001 and the nine months ended September 30, 2002, respectively.
- 3. The adjustments to the unaudited pro forma condensed consolidated statement of financial position reflect the elimination of the unaudited consolidated assets and liabilities of Cognizant as of September 30, 2002 (See Cognizant Financial Statements beginning on page F-1 of the offering circular-prospectus) and the recognition of an intercompany payable to Cognizant in the amount of \$2,433.
- 4. In addition, the pro forma adjustments to the unaudited pro forma condensed consolidated statement of financial position reflect:
 - A. The elimination of the minority interest in Cognizant as of September 30, 2002 in the amount of \$64, 673.
 - B. (i) The acquisition of 36,540 shares of IMS Health common stock pursuant to the exchange offer, assuming the exchange offer is fully subscribed, recorded at a cost equal to the closing price on January 8, 2003 of \$16.64 per share, amounts to \$608,026.

- (ii) The estimated tax-free gain on the disposal of IMS Health's investment in Cognizant in the amount of \$522,460, after consideration of the cost basis of \$72,566.
- (iii) The accrual of the estimated direct and incremental costs of the exchange offer in the amount of \$13,000.

The gain on disposal is predicated upon the closing price of the IMS Health common stock on the exchange offer expiration date and the number of shares accepted in the exchange offer. The actual amount of gain may differ significantly based on the number of shares of IMS Health stock accepted and closing price for IMS Health common stock on the exchange offer expiration date.

5. The unaudited pro forma condensed consolidated financial information assumes that 36,540 shares of IMS Health common stock are acquired in the exchange offer. If we assume that only 27,400 shares of IMS Health common stock are acquired, the minimum amount that IMS Health will accept, IMS Health would retain a number of Cognizant shares representing approximately 13.8% of Cognizant's outstanding common stock. The estimated gain on disposal of the investment in Cognizant would be approximately \$390,000 and IMS Health would have a remaining cost basis in Cognizant of approximately \$18,000.

7

Item 6. Not Applicable.

Item 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(a) Financial Statements.

None

(b) Pro Forma Financial Information.

None

(c) Exhibits.

None

Item 8-9. Not Applicable.

8

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

IMS HEALTH INCORPORATED

By: /s/ Robert H. Steinfeld

Name: Robert H. Steinfeld

Title: Senior Vice President, General Counsel

and Corporate Secretary

Date: January 16, 2003